Company intelligence / Profile preview

Antibe Therapeutics Inc.

Toronto, Ontario, Canada

Ownership: Private
Employees: ~11
Development stage: Phase 2

Overview

The company's lead drug otenaproxesul completed a PK/PD study with positive safety results showing no adverse safety signals or elevations in liver enzymes. The company was preparing for a Phase II trial in Q1 2024 for acute pain, but as of April 2024, the company was under CCAA proceedings (bankruptcy protection).

Therapeutic areas: Women's HealthGastroenterologyNeurologyRheumatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

otenaproxesul

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Antibe Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antibe Therapeutics Inc..

Explore the full profile